Because most cases of sporadic PTC irrespective of the histopathology share BRAFV600E as an oncogenic driver and secondary mutations of pathogenic significance, e.g., of TERT and TP53, usually are late events implicated in tumor progression, it is rationale to infer the existence of yet unknown factors that likely contribute to the development of different PTC tumor phenotypes. The gene discussed is TP53; the disease is neoplasm.